AGP Picks
View all

Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

Press releases published on August 12, 2026

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Kamada Announces Planned Transition of Chief Financial Officer
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health & Wellness Today New York

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.